NCT06269900

Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype

Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype, an International Phase III, Double-blind, Placebo-controlled, Randomized Trial

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 450 (estimated)
• Sponsor: Nantes University Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Determine the efficacy of dexamethasone plus standard of care (SOC) as compared to placebo plus SOC for treating severe hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype; It's an international phase III, double-blind, placebo-controlled, randomized trial.

Conditions

• Hospital Acquired Pneumonia

Interventions

Type	Name	Description
DRUG	Dexamethasone	Dexamethasone phosphate injection is given as a slow injection or infusion (intravenous drip) into the veins.
DRUG	Placebo	Placebo injection is given as a slow injection or infusion (intravenous drip) into the veins.

Timeline

• Start date: 2024-03-26
• Primary completion: 2026-03-14
• Completion: 2026-08-15
• First posted: 2024-02-21
• Last updated: 2025-08-11

Locations

26 sites across 1 country: France